Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Modulation of amyloid β-protein clearance and Alzheimer’s disease susceptibility by the LDL receptor–related protein pathway
David E. Kang, … , Robert Katzman, Edward H. Koo
David E. Kang, … , Robert Katzman, Edward H. Koo
Published November 1, 2000
Citation Information: J Clin Invest. 2000;106(9):1159-1166. https://doi.org/10.1172/JCI11013.
View: Text | PDF
Article

Modulation of amyloid β-protein clearance and Alzheimer’s disease susceptibility by the LDL receptor–related protein pathway

  • Text
  • PDF
Abstract

Susceptibility to Alzheimer’s disease (AD) is governed by multiple genetic factors. Remarkably, the LDL receptor–related protein (LRP) and its ligands, apoE and α2M, are all genetically associated with AD. In this study, we provide evidence for the involvement of the LRP pathway in amyloid deposition through sequestration and removal of soluble amyloid β-protein (Aβ). We demonstrate in vitro that LRP mediates the clearance of both Aβ40 and Aβ42 through a bona fide receptor-mediated uptake mechanism. In vivo, reduced LRP expression is associated with LRP genotypes and is correlated with enhanced soluble Aβ levels and amyloid deposition. Although LRP has been proposed to be a clearance pathway for Aβ, this work provides the first in vivo evidence that the LRP pathway may modulate Aβ deposition and AD susceptibility by regulating the removal of soluble Aβ.

Authors

David E. Kang, Claus U. Pietrzik, Larry Baum, Nathalie Chevallier, David E. Merriam, Maria Z. Kounnas, Steven L. Wagner, Juan C. Troncoso, Claudia H. Kawas, Robert Katzman, Edward H. Koo

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
LRP does not alter the secretion of Aβ in cultured cells. LRP+/– and LRP...
LRP does not alter the secretion of Aβ in cultured cells. LRP+/– and LRP–/– fibroblasts transfected with human APP695 were generated as described. (a) To determine whether LRP levels contribute to changes in production and secretion of Aβ, APP-transfected LRP+/– and LRP–/– cells were metabolically labeled with 35S-methionine for 20 minutes and immunoprecipitated with an Ab specific for APP (upper panel). In parallel experiments, medium was conditioned for 24 hours, and the amount of secreted Aβ was analyzed by immunoprecipitation (3134), followed by Western blotting (26D6) (lower panel). (b) To distinguish between Aβ secretion and LRP-dependent Aβ clearance within a 24-hour period, APP overexpressing LRP+/– and LRP–/– cells were treated with or without RAP (1 μM), and the medium was quantitated for the amount of Aβ by ELISA. Graph shows a representative experiment (n = 3) with means and SEM. (c) Confluent cultures of APP overexpressing LRP+/+ and LRP–/– fibroblasts were incubated with or without activated α2M (100 nM) in serum-free medium to induce uptake of Aβ through LRP. RAP (1 μM), an antagonist for all known LRP ligands, was added to block α2M-LRP–mediated effects. After 48 hours, medium was collected and analyzed for levels of Aβ by sandwich ELISA assay. Aβ levels are normalized to the no-treatment group of each cell line. Experiments were performed three times in triplicate. Error bars represent SEM.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts